Form D · Biotechnology
Walking Fish Therapeutics, Inc.
South San Francisco, CA · CIK 0001882704
Offering snapshot reported Mar 3, 2022 · SEC filing
- Reported sold
- $12.7M Offering amount: $23.4M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 16, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 3, 2022 | Initial | $12,699,998 | No comparison | 3 | SEC filing |
| Sep 14, 2021 | Initial | $28,787,041 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-435701
Source: Form D, filed Mar 3, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Franklin Berger | Director |
| Antonin De Fougerolles | Director |
| Daniel Janse | Director |
| Alexis Ji | Director |
| Manish Kothari | Director |
| Lewis T. Williams | Director, Executive |
| Momo Wu | Director |
| Stella Xu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
280 Utah Avenue, Suite 250
South San Francisco, CA, 94080
South San Francisco, CA, 94080